Professional Essentials · Free · No registration
Aesthetic medicine and rheumatic disease
Individual assessment of disease, medicines, tissue and procedure, with realistic consent and a clear plan for complications.
1. Start with the clinical question
Appearance-related concerns deserve a clinical conversation. Rheumatic disease can change skin, hair, facial movement and confidence; cosmetic treatment may address an important personal goal. A 2026 cross-sectional survey documents that interest, but surveys cannot establish procedural safety. “Autoimmune disease” alone is neither a universal prohibition nor adequate clearance.
Define the proposed benefit: correcting an established contour deficit differs from treating active inflammatory swelling, scarring alopecia or progressive weakness. Establish the diagnosis first. Record current systemic and local disease activity, previous healing problems, infection, tissue perfusion, allergies, prior procedures and implanted materials. The assessment should explain why this particular procedure is reasonable now, what uncertainty remains, and which findings would change the decision.
Separate a labeled contraindication from a precaution, an unstudied population and a clinic’s own limitation. Normal inflammatory markers do not demonstrate healthy local tissue or negate product warnings. There is no single laboratory panel or universal remission interval that clears every rheumatic patient for every cosmetic intervention.
Ask what the patient would regard as a worthwhile change and how it would be assessed. Discuss the likely duration of benefit, repeated-treatment burden and uncertainty in patients who differ from trial participants. Photographs can document the baseline with consent, but an image alone cannot establish disease inactivity. A consultation should leave room to decline treatment without losing access to ordinary rheumatology care.
Contraindications and clinical selection → Open access Choose “For professionals” in the article.
2. Protect disease control when planning
Reconcile prescription drugs, nonprescription products and injections from other clinicians. Glucocorticoids, immunomodulators, anticoagulants and drugs affecting neuromuscular transmission raise different questions; “hold all rheumatology medicines” is not an acceptable plan. Consider procedure depth, wound burden, infection consequences, disease stability and the consequences of a flare.
The 2022 ACR/AAHKS perioperative guideline concerns elective hip and knee arthroplasty. Its medication schedules should not automatically be transferred to a small cosmetic injection or energy-based treatment. Agree any interruption and restart with the prescribing clinician and proceduralist. Do not abruptly stop long-term glucocorticoids.
Bruising risk and thrombosis risk must be weighed together. A patient taking anticoagulation for thrombotic antiphospholipid syndrome needs a coordinated decision; a cosmetic preference does not justify an unsupervised interruption. When an elective procedure requires a medically unacceptable treatment change, deferral or a less invasive option can be the appropriate outcome.
Medication and procedure planning → Open access Choose “For professionals” in the article.
3. Botulinum toxin: assess function
The BOTOX Cosmetic prescribing information identifies injection-site infection and relevant hypersensitivity as contraindications. It also warns about neuromuscular disorders and pre-existing swallowing or breathing difficulties. Assess baseline weakness, dysphagia, respiratory limitation and eyelid closure rather than relying on a rheumatic diagnosis alone. Myositis requires particular functional assessment; it is not interchangeable with a neuromuscular-junction disorder.
Ask about therapeutic toxin injections elsewhere, their timing, and medicines such as aminoglycosides or muscle relaxants. Units from different botulinum toxin products are not interchangeable. In patients with substantial ocular dryness, periocular treatment needs attention to blinking and corneal protection. Patients must know that new swallowing, speech or breathing difficulty after injection requires immediate medical assessment, including when symptoms begin after leaving the clinic.
Botulinum toxin: professional companion → Open access Choose “For professionals” in the article.
4. Fillers and implanted materials
Choose by material, indication, anatomical site and reversibility. FDA filler guidance emphasizes the uncommon but serious consequences of accidental intravascular injection: skin necrosis, blindness and stroke. Controlled rheumatic disease does not remove these anatomical risks. The injector needs product-specific training and a workable emergency pathway.
Hyaluronic-acid filler and collagen-stimulating implants are different interventions. The availability of hyaluronidase does not guarantee rescue of vascular or visual injury. Poly-L-lactic acid and calcium hydroxylapatite cannot simply be dissolved with the same approach. Avoid adding material to unexplained swelling or an area with uncertain previous filler until its cause and procedural history are clarified.
The US Sculptra instructions specify immunocompetent subjects for aesthetic facial indications and state that safety and effectiveness have not been evaluated in connective-tissue disease or during immunosuppressive therapy. That evidence gap must be discussed explicitly. It should not be converted into either proof of safety or a claim that every autoimmune condition is a labeled contraindication.
Hyaluronic-acid fillers: professional companion → Open access Choose “For professionals” in the article.
5. Match the device to the tissue
Laser, intense pulsed light, mechanical microneedling and radiofrequency microneedling have different mechanisms and tissue effects. A device that does not emit ultraviolet light is not thereby proven safe for a patient with active lupus skin disease. Identify whether the target represents active inflammation, established damage or an unrelated dermatologic disorder; involve dermatology when that distinction is uncertain.
FDA microneedling information highlights suitability concerns in autoimmune disease and immunosuppression, and states that cleared devices have not been approved to deliver drugs, cosmetics or platelet-rich plasma into skin. Autologous material does not eliminate infection or procedural risk. Diagnose hair loss before proposing injections; suspected inflammatory or scarring alopecia needs disease-directed assessment.
An FDA communication dated October 15, 2025 describes serious reported complications with certain radiofrequency microneedling uses, including burns, scarring, fat loss and nerve injury. Discuss the exact device, settings, operator experience and intended tissue depth. Marketing terms such as “regenerative” do not replace evidence for the proposed procedure in the patient’s clinical setting.
Plan the clinical setting as carefully as the device. Confirm who evaluates an unexpected wound, who can assess worsening systemic symptoms, and how urgent specialist care will be obtained. Avoid stacking several poorly studied procedures in one session when doing so would make a complication difficult to interpret or manage.
Lasers, IPL and microneedling → Open access Choose “For professionals” in the article.
6. Make follow-up part of consent
A disease-specific plan is more useful than generic clearance. In systemic sclerosis or morphea, characterize local fibrosis and perfusion; in Sjögren disease, account for ocular and oral function; in inflammatory myopathy, prioritize strength and swallowing. Cosmetic improvement should not be promised to correct the underlying systemic disorder. Discuss alternatives, including skin care, camouflage, treatment of active disease or choosing no procedure.
Document the exact product or device, lot where relevant, sites, baseline findings and agreed medication plan. Provide an expected recovery trajectory, written instructions and a reachable clinician. Increasing pain, blanching or dusky skin after filler requires urgent assessment; any visual change or focal neurological deficit warrants emergency care. New respiratory or swallowing symptoms after toxin also require immediate escalation.
Delayed nodules, erythema or swelling are not automatically a rheumatic flare. Evaluate infection, material-related reactions and other causes before reflexively increasing immunosuppression. Follow-up should determine whether the intended benefit occurred and whether further intervention remains justified.
Aftercare and complications → Open access Choose “For professionals” in the article.
Sources and clinical verification
Clinically reviewed on October 4, 2026. Product labels and device authorizations are specific to jurisdiction, formulation and indication.
- Almaghlouth et al. Cosmetic procedures in rheumatic diseases: cross-sectional survey (2026).
- ACR/AAHKS perioperative medication guideline summary (2022).
- BOTOX Cosmetic: US prescribing information.
- FDA: Dermal fillers.
- Sculptra: US instructions for use.
- FDA: Microneedling devices.
- FDA: Potential risks of certain radiofrequency microneedling uses (October 15, 2025).